# NEXT_SESSION.md — Official Handoff (Single Entry Point)

**Rewritten in full on 2026-07-16 as an official session close.** This document, together with
`CHANGELOG.md`, `ROLLING_HEALTH_BACKTEST_HANDOFF.md`, `PHASE_6_9_ROLLING_HEALTH_GATED_BACKTEST_
REPORT.md`, `CURRENT_XAUUSD_12M_RELEVANCE_REPORT.md`, and `PHASE_6_9A_STRATEGY_EVIDENCE_FLOW_AUDIT_
SPEC.md`, is designed to be FULLY SELF-CONTAINED — a brand-new chat must be able to reconstruct this
project's entire state from these documents alone, with no access to any prior conversation. Every
fact below was verified directly against `git log`/`git status`/`git diff` at close time — nothing
here is assumed or carried over unverified.

**Read, in order: `PHASE_6_9_ROLLING_HEALTH_GATED_BACKTEST_REPORT.md`, then `CURRENT_XAUUSD_12M_
RELEVANCE_REPORT.md`, then `PHASE_6_9A_STRATEGY_EVIDENCE_FLOW_AUDIT_SPEC.md`** — together they are
this session's complete story: a rolling-gate methodology found unworkable, a follow-up current-
relevance snapshot that independently confirms the underlying evidence is too sparse, and a specified
(not started) diagnostic phase to determine WHY.

---

## A. Project mission

**AI Quant Research Lab → AI Trader.** Two systems, physically separated by design:

- **Research Lab** (`code/`, `results/`, `knowledge/`) discovers and validates trading strategies
  against historical XAUUSD data. **Frozen and stable; never touched during AI Trader work** —
  verified 0-diff live at this session's close (§F).
- **Strategy Library** (`knowledge/strategies/`) publishes 51 strategy specs (S1–S51). **All 43
  runtime-eligible strategies** are migrated to Strategy Interface v1 and have real runtime
  evaluators — Wave B is COMPLETE (unchanged since Phase 6.9).
- **AI Trader** (`ai_trader/`) is the execution system. All six live pipeline modules are READY.
  The **Simulation Framework** (Phase 6.7) is READY, extended in the Phase 6.9 session with one
  disclosed, additive, backward-compatible fix (unchanged this session). The **Strategy Runtime**
  framework is READY and proven end-to-end for all 43 strategies.
- **Strategy Health System** (`ai_trader/strategy_health/`) — a rolling-window, recent-performance-
  based scoring and classification system. Its own scoring methodology is UNCHANGED this session
  (frozen, per explicit CEO instruction). This session's relevance audit reused two of its existing
  functions read-only (`compute_window_metrics`, `score_window`) — no new library code was added.

**Simulation-first is mandatory (standing CEO directive, non-negotiable):** the AI Trader must prove
robust historical profitability in simulation before any Broker Adapter/MT5/live execution work
begins. Wave D's first full-portfolio run (all 43 strategies, static, no health-gating, full 3.6-year
history): +15.66% return, Sharpe 1.196, max drawdown 6.16%, 513 trades
(`WAVE_D_PORTFOLIO_SIMULATION_REPORT.md`) — reproduced EXACTLY, fresh, during Phase 6.9.

**Phase 6.9 — Rolling Health-Gated Backtest — COMPLETE, closed as a VALID NEGATIVE RESULT** (prior
session). The frozen rolling-gating methodology produced an empty ACTIVE roster at all 32
post-bootstrap monthly checkpoints over the full 3.6-year history. Full detail: `PHASE_6_9_ROLLING_
HEALTH_GATED_BACKTEST_REPORT.md`.

**Current XAUUSD 12-Month Relevance Audit — COMPLETE, closed as a VALID NEGATIVE, UNDER-SAMPLED
RESULT (this session).** A narrower, current-market-only snapshot (NOT a rolling gate, NOT a
multi-year aggregate): using the most recent complete 12 months that lie entirely outside the sealed
terminal holdout (**2024-10-23 → 2025-10-23**, 23,639 M15 bars, disclosed NOT out-of-sample relative
to strategy discovery — see `CURRENT_XAUUSD_12M_RELEVANCE_REPORT.md` §1), classification came back:

| Classification | Count |
|---|---|
| CURRENTLY_STRONG | **0** |
| CURRENTLY_USABLE | **0** |
| CURRENTLY_WEAK | **4** (S1, S39, S44, S46) |
| INSUFFICIENT_EVIDENCE | **39** (20 of which took ZERO trades in the entire 12-month window) |

Portfolio tests (A=all 43 / B=STRONG-only / C=STRONG+USABLE / D=all-except-WEAK, same $2,000/5%-risk/
cost-model/seed=1 config) showed **highly concentrated, path-dependent results**: B and C are
trivially empty (0 qualifying strategies); D numerically beats A on every metric but 94.4% of D's net
profit comes from ONE strategy (S40, itself INSUFFICIENT_EVIDENCE) trading 26x more often purely
because excluding S1/S39/S44/S46 freed up the single shared XAUUSD position slot; A's own result is
dominated by 3 outlier trades and one outlier month. **No current deployment roster can be justified
from this audit.** No strategy was changed, promoted, or eliminated; no threshold/risk/scoring/
execution rule was altered; the sealed holdout was not opened. Full detail: `CURRENT_XAUUSD_12M_
RELEVANCE_REPORT.md`.

**Phase 6.9A — Strategy Evidence Flow Audit — SPECIFIED this session (documentation only), NOT
STARTED, NOT IMPLEMENTED.** Both audits above converge on the same open question: strategies aren't
failing because they're bad, they're failing to accumulate evidence at all. Phase 6.9A's own
objective is to find out WHY — per-strategy conversion rates through every pipeline stage (raw setup
detection → actionable signal → context-blocked → shared-slot-blocked → Scoring Engine rejection →
Risk Manager denial → unfilled order → completed trade), separating genuine low market frequency from
shared-slot suppression, scoring suppression, risk suppression, execution suppression, and
insufficient historical data. Full specification: `PHASE_6_9A_STRATEGY_EVIDENCE_FLOW_AUDIT_SPEC.md`.
**Do not begin implementing Phase 6.9A, Phase 6.10, Wave C, Learning Engine, Broker Adapter, MT5, or
live/paper trading without its own dedicated CEO approval — this document does not grant it.**

**Phase 6.10 — Sparse-Evidence Strategy Governance Design — still CEO-recommended, NOT STARTED, NOT
SCOPED FOR IMPLEMENTATION** (unchanged from Phase 6.9's own close; see §H). Phase 6.9A is a narrower,
diagnostic PREREQUISITE to 6.10 — it explains WHY evidence is sparse; 6.10 would design WHAT to do
about it. Sequencing between them is the CEO's own call, not decided by this document.

---

## B. Official Git state (verify live — do not trust blindly)

```
Repository path:  C:\Users\MEDION GAMING\ai_quant_lab-research-main
Branch:           ai-trader-implementation
HEAD (pre-close): 04d616bee5f766f5fac6540e2e174b273ee66899 (last commit before this session's own close commit)
Working tree:     clean (verified live at close)
```

**Note**: the close commit itself (the relevance audit report + this file + `CHANGELOG.md`) lands ONE
commit after `04d616b` — run `git log -1` to see the exact current HEAD; do not assume it is still
`04d616b` in any future session. `PHASE_6_9A_STRATEGY_EVIDENCE_FLOW_AUDIT_SPEC.md` is written this
session but deliberately left UNCOMMITTED (per the CEO's own "prepare the specification... stop" — it
awaits its own explicit review/commit instruction, the same pattern the relevance report itself
followed before its own commit was authorized).

**Re-verify `git log -1`/`git status --porcelain` directly before trusting any git-state claim
here** — the same discipline every prior handoff in this repository has followed.

## C. Completed work this session

- **Current XAUUSD 12-Month Relevance Audit** (§A) — a fresh, standalone `SimulationHarness` run (not
  a continuation of any prior run) scoped to exactly the 2024-10-23→2025-10-23 window, for portfolio
  variant A (all 43) and re-run 3 more times for variants B/C/D with different `strategy_id_filter`
  values. Per-strategy metrics reuse `ai_trader.strategy_health.metrics.compute_window_metrics` and
  `scoring.score_window` read-only (no Health System code added or modified this session — Phase 6.9's
  own `rolling_gate.py` addition was the prior session, unchanged here).
- Diagnostic artifacts preserved at repo root (same precedent as Phase 6.9):
  `relevance12m_run.py`, `relevance12m_run_bcd.py`, `relevance12m_perstrategy.py` (orchestrator/
  analysis scripts) and `relevance12m_portfolioA.json`, `relevance12m_portfolioBCD.json`,
  `relevance12m_perstrategy.json` (raw output, every trade's full record).
- **`PHASE_6_9A_STRATEGY_EVIDENCE_FLOW_AUDIT_SPEC.md`** written — a documentation-only specification,
  no code, no strategy/pipeline change. See §A and the document itself for full scope.
- No `ai_trader/` source code was touched this session (unlike Phase 6.9, which added `rolling_
  gate.py` and the `harness.py` overlay-isolation fix) — this session was analysis + documentation
  only, reusing infrastructure exactly as Phase 6.9 left it.

Phase 6.9's own completed work (the `harness.py` fix, `rolling_gate.py`, the anti-lookahead test, the
full rolling-gated backtest) — unchanged, full detail in `PHASE_6_9_ROLLING_HEALTH_GATED_BACKTEST_
REPORT.md` and the prior `CHANGELOG.md` entry. Prior-prior sessions' work (Phases 6.1–6.8, Wave D,
Wave D Audit, Strategy Health System build) — unchanged, full detail in `ROLLING_HEALTH_BACKTEST_
HANDOFF.md` §2–§6.

## D. Strategy Health System — current status

**Scoring methodology UNCHANGED this session** (frozen, per explicit CEO instruction, same as Phase
6.9 — see `ROLLING_HEALTH_BACKTEST_HANDOFF.md` §5 for full methodology, still accurate). This session
exercised it a THIRD way: not the one-time full-lifetime snapshot (`STRATEGY_HEALTH_SYSTEM_REPORT.md`:
2 ACTIVE/34 WATCHLIST/7 PROBATION/0 DISABLED as of 2026-07-13), not the rolling time-evolving mode
(Phase 6.9: empty roster throughout), but a **single-window, current-relevance-only** scoring (this
session: 0 STRONG/0 USABLE/4 WEAK/39 INSUFFICIENT_EVIDENCE as of 2025-10-23, using ONLY that window's
own 12-month evidence, no blending with 3m/6m, no trend-bump). All three are different, valid readings
of the same frozen scoring machinery over different data slices — do not confuse them, and do not
average or reconcile them into one number; each answers a different question.

## E. Global implementation statistics

Unchanged from Phase 6.9's own close (no `ai_trader/` source code touched this session):

```
pytest ai_trader/ -q
1571 passed

mypy --strict ai_trader/ --exclude 'tests/'
Success: no issues found in 165 source files

coverage run --source=ai_trader -m pytest ai_trader/ -q
coverage report --omit="*/tests/*"
TOTAL   9648 stmts   432 miss   96%
```

## F. Protected invariants — confirmed untouched (verified this session, live)

- `code/`, `results/` (Research Lab) — 0-diff, confirmed via `git status --porcelain -- code/
  results/` (empty).
- `knowledge/` — untouched.
- The six live pipeline modules' production code — untouched.
- The Strategy Health System's own scoring methodology — byte-for-byte unmodified; only read from,
  never edited, this session.
- **No `ai_trader/` source file was touched at all this session** — a stricter invariant than Phase
  6.9's own close (which had one disclosed `harness.py` fix); this session was pure analysis +
  documentation over the infrastructure Phase 6.9 already left in place.
- No strategy was changed, promoted, or eliminated. No threshold, risk parameter, scoring weight, or
  execution rule was altered.
- Terminal holdout — SEALED, untouched, NOT opened for this audit (the analysis window was
  deliberately chosen to exclude it entirely — see §A and the relevance report §1).
- No scratch/temporary files beyond the explicitly-preserved `phase69_*`/`relevance12m_*` diagnostic
  artifacts (a deliberate, CEO-instructed exception to the usual "delete scratch scripts after report
  capture" discipline, so both this session's and Phase 6.9's own negative results stay fully
  reproducible).

## G. Technical debt / known limitations

Everything already listed in `ROLLING_HEALTH_BACKTEST_HANDOFF.md` §7 and Phase 6.9's own NEXT_SESSION
entry, PLUS, newly confirmed by this session's own audit:

- **The evidence-sparsity problem is confirmed independently in a SECOND, differently-designed
  evaluation** (a single current-relevance window, not a rolling gate) — 20 of 43 strategies took
  literally zero trades in a full 12-month window, and only 4 had enough evidence to be judged at all,
  all four scoring WEAK. This is not an artifact of the rolling-gate mechanism specifically (Phase
  6.9's own finding) — it reproduces under a completely different evaluation design, strengthening the
  conclusion that the underlying issue is trade-frequency scarcity itself, not any one gating method.
- **The single-shared-symbol-slot path-dependence effect (Wave D Audit, Phase 6.9) reproduces again
  here**: portfolio D's 94.4%-from-one-strategy concentration is a direct, confirmed instance of it,
  now observed a third time across three independent analyses.
- **WHY strategies fail to accumulate evidence is still not understood at a mechanistic level** — is
  it genuine market rarity, or is evidence being suppressed by the shared slot, the Scoring Engine, the
  Risk Manager, or execution, before it ever has a chance to become a trade? This is exactly Phase
  6.9A's own objective (§A) — not yet answered.
- Execution costs still modeled as zero everywhere (unchanged limitation).
- Portfolio-level `max_drawdown_R` still unresolved (unchanged limitation).

## H. Immediate next phase(s)

**Phase 6.9A — Strategy Evidence Flow Audit.** SPECIFIED (documentation only,
`PHASE_6_9A_STRATEGY_EVIDENCE_FLOW_AUDIT_SPEC.md`), NOT STARTED, NOT IMPLEMENTED. See that document
for the full spec: per-strategy pipeline-stage conversion rates (raw setups → actionable signals →
context-blocked → shared-slot-blocked → Scoring Engine rejected → Risk Manager denied → unfilled
orders → completed trades), a hypothetical isolated-slot trade count (measured, not used to change
production behavior), and a 6-category suppression classification (A: genuine low market frequency;
B: shared-slot suppression; C: scoring suppression; D: risk suppression; E: execution suppression; F:
insufficient historical data) for every strategy.

**Phase 6.10 — Sparse-Evidence Strategy Governance Design.** CEO-recommended, NOT STARTED, NOT SCOPED
FOR IMPLEMENTATION — unchanged from Phase 6.9's own close. Proposed menu to study (no selection made,
nothing implemented): ACTIVE+WATCHLIST differentiated risk; hierarchical/Bayesian pooling; longer
evidence windows; minimum exploration allocation; portfolio-level Health scoring; shadow-mode evidence
accumulation; regime-conditioned evidence; incumbency-until-negative-evidence policies.

Do not begin any part of either phase without explicit CEO approval; this document does not grant that
approval, it only prepares the ground for the CEO's own decision.

## I. Exact next-session order

1. **Read this document in full first.**
2. **Verify Git state directly** — `git branch --show-current`, `git log -1`, `git status --porcelain`.
3. **Read, in order**: `PHASE_6_9_ROLLING_HEALTH_GATED_BACKTEST_REPORT.md`, `CURRENT_XAUUSD_12M_
   RELEVANCE_REPORT.md`, `PHASE_6_9A_STRATEGY_EVIDENCE_FLOW_AUDIT_SPEC.md`.
4. **Read `ROLLING_HEALTH_BACKTEST_HANDOFF.md`** for the architecture/methodology both prior audits
   tested (still accurate, unchanged).
5. **Read `CHANGELOG.md`'s own top entry** for this session's exact facts, re-verified live rather
   than trusted, per this repository's own standing discipline.
6. **Report the reconstructed state back to the CEO** before proceeding on anything new.
7. Once confirmed, the CEO's own next direction determines what happens — most likely either
   approving Phase 6.9A's implementation, scoping Phase 6.10, or a different direction the CEO
   chooses instead. Stop and ask before starting any of them.

---

*Prior-session narrative history (Phases 6.1–6.9, Wave D, the Wave D Audit, the Strategy Health
System's own build, the Rolling Health-Gated Backtest) remains available in git history of this file
(`git log -p -- NEXT_SESSION.md`) and in each phase's own dedicated report/handoff document listed
above.*
